MBBS, FACEM, FCICM, PhD
Matt is a senior consultant in Intensive Care Medicine and Emergency Medicine who has worked in Geelong for over 10 years. He has provided a VMO service at St John of God Hospital, consults at the Geelong Hospital Emergency Department and maintains a research program at the Royal Adelaide Hospital ICU.
Matt has a particular interest in pre-clinical research and has completed a PhD thesis describing the thyroid hormone changes in critical illness. Otherwise it is music, horses, Essendon Football Club or running around 5 children that occupies his time.
Head of Research
Matt has a particular interest in pre-clinical research and has completed a PhD thesis describing the thyroid hormone changes in critical illness. Otherwise it is music, horses, Essendon Football Club or running around 5 children that occupies his time.
Latest news:
-
Thursday, August 26, 2021 - 01:57
JAMA BaSICS rate: Slower vs faster fluid challenge in critically ill patients not significantly reduce 90-day mortality. In addition there was a lower use of vasopressors on day 3 in the slower infusion rate group. Adds to SPLIT and SMART trials.
Monday, August 23, 2021 - 13:54NEJM Convalescent plasma RCT for high-risk patients present to ED within 7 days after the onset of symptoms = no difference disease progression
Monday, August 23, 2021 - 12:27NEJM VITT review 237 suspected from 24 million Oxford-Astra Zeneca doses, incidence at least 1:100,000 >50 years, 1:50,000 <50 years, occurs 5-30 days after first dose. Extensive thrombotic sites, cerebral venous thrombosis dominant. Low platelets, increased D-dimer, reduced fibrinogen associated worse outcomes. Overall case fatality rate 23%, highest in patients with both ICH and platelet count below 30,000. No therapeutic options proven effective, although IVIG, corticosteroids, plasma exchange, and non-heparin anticoagulation are used.
Sunday, August 22, 2021 - 19:03JC DOREMI RCT reports no difference in composite primary outcome with milrinone vs dobutamine for cardiogenic shock (49% M vs 54% D, RR, 0.90; 95% CI, 0.69 to 1.19; P=0.47). No difference in secondary outcomes. It was powered to detect a large effect.
Sunday, August 22, 2021 - 11:21REMAP-CAP, ACTIV-4a, and ATTACC harmonised multiplatform, randomized trial 2244 non-ICU patients with COVID- for every 1000 patients, therapeutic anticoagulation vs thromboprophylaxis expected to result in 40 additional patients surviving to hospital discharge without organ support, and 7 major bleeds.